Zika (Experimental)
Zika Virus — Experimental Vaccine Candidates
Platform: Pathogen — No Licensed Vaccine
Mosquito-borne flavivirus linked to microcephaly and Guillain-Barré syndrome — vaccine candidates are in clinical trials with no licensed product.
EXPERIMENTAL — No licensed vaccine or therapeutic currently approved.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗
Zika virus is an arbovirus which is a member of the virus family Flaviviridae. It is spread by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Ziika Forest of Uganda, where the virus was first isolated in 1947. Zika virus shares a genus with the dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Since the 1950s, it has been known to occur within a narrow equatorial belt. From 2007 to 2016, the virus spread westward, across the Pacific Ocean to the Americas, leading to the 2015–2016 Zika virus epidemic.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗No Semantic Scholar results retrieved.